X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
X4 Pharmaceuticals (Nasdaq:XFOR) announced that management will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 3:45 p.m. ET.
Rhea-AI Summary
X4 Pharmaceuticals (Nasdaq:XFOR) announced that management will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 3:45 p.m. ET. A live and archived webcast of the presentation will be available via the Investors section of the company’s website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – XFOR
In the May 27 session, XFOR gained 0.75%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference date
- June 4, 2026
- Jefferies Global Healthcare Conference presentation time 3:45 p.m. ET
- Shelf registration size
- $300,000,000
- Maximum aggregate offering amount under Form S-3 shelf
- ATM program size
- $75,000,000
- At-the-market sales agreement with Jefferies for common stock
- 4WARD trial size
- 176 patients
- Target enrollment for global Phase 3 4WARD chronic neutropenia trial
- Q1 2026 revenue
- $2.7M
- Total revenue in Q1 2026 per 10-Q
- Q1 2026 net loss
- $20.2M
- Net loss for Q1 2026 per 10-Q
- Quarter-end cash
- $233.7M
- Cash, cash equivalents and short-term marketable securities at 3/31/2026
- Perceptive ownership
- 7.3%
- Beneficial ownership of common stock reported in Schedule 13G/A
Historical Context
-
Q1 2026 results, EU XOLREMDI authorization, cash runway through 2028.
-
European Commission marketing authorization for XOLREMDI in WHIM syndrome.
-
Inducement option awards totaling 32,000 shares under 2019 plan.
-
Q4 and 2025 results, 4WARD Phase 3 progress, strong cash position.
-
Management fireside chat at Leerink Global Healthcare Conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 3:45 p.m. ET.
A link to the live and archived webcast may be accessed on X4 Pharmaceuticals’ website under the Investors section: Events and Presentations.
About X4 Pharmaceuticals
X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is approved in the U.S. and EU as XOLREMDI® for patients with WHIM syndrome. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.
X4 Investor Contact:
Remy Bernarda
Jenny Kobin
IR Advisory Solutions
ir@x4pharma.com
Source: X4 Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.